Inceptua partners with TikoMed to widen global access to investigational ALS therapy ILB
Inceptua Group selected to manage TikoMed’s Named Patient Program for investigational therapy ILB in amyotrophic lateral sclerosis (ALS)
27 Aug 2026
Inceptua Group (Inceptua) and TikoMed AB (TikoMed) have announced the launch of a Named Patient Program for TikoMed’s investigational drug, ILB®, for eligible patients with amyotrophic lateral sclerosis (ALS).
ALS, also known as Lou Gehrig's disease, is a progressive, fatal neurodegenerative disorder. It progressively damages motor neurons in the brain and spinal cord, leading to severe muscle weakness, loss of voluntary movement, and eventually respiratory failure. ALS is a rare disease affecting about 2-3 in every 100,000 individuals worldwide. There is currently no cure for ALS.
A Named Patient Programme is a compliant way for medicines that are not approved in their country of intended use to be made available for patients who either have no alternative treatment option or have exhausted all other treatment options available in their country of residence.
The ILB® Named Patient Program is designed to provide eligible patients with a pathway to access ILB® prior to regulatory approval, where permitted under local regulations.
Stuart Bell, Executive Vice President, Inceptua Early Access said, "Inceptua is proud to support TikoMed in making its investigational product, ILB®, available whilst it is still going through the clinical trial development process. Patients with ALS have very limited treatment options."
Björn Pilström, CEO and CMO of TikoMed said, "TikoMed is happy to collaborate with Inceptua on this programme to help support access to ILB® for eligible patients with no alternative treatments for a life-threatening disease. Inceptua has a long and proven track record of providing Named Patient Programmes for the pharmaceutical industry and we are confident this collaboration will help provide an important access pathway for eligible patients across the globe."
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Tags
Frequently asked questions
Show frequently asked questions
What is the ILB Named Patient Program for eligible ALS patients?
The program provides eligible patients with amyotrophic lateral sclerosis (ALS) a pathway to access TikoMed’s investigational drug ILB® before regulatory approval, where local regulations permit. It is intended for patients who have no alternative treatment or have exhausted available treatment options in their country.
Why are Inceptua Group and TikoMed collaborating on access to ILB?
Inceptua Group and TikoMed launched the program to support global access to ILB® for eligible ALS patients while the investigational therapy remains in clinical trial development. TikoMed selected Inceptua because of its long, proven track record in providing Named Patient Programmes for the pharmaceutical industry.
What is amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease?
ALS is a rare, progressive and fatal neurodegenerative disorder affecting approximately 2–3 people per 100,000 worldwide. It damages motor neurons in the brain and spinal cord, causing severe muscle weakness, loss of voluntary movement and eventually respiratory failure. There is currently no cure for ALS.